Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2004, Vol. 104, No. 1, pp. 296.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fenouillet, E.
Right arrow Articles by Jones, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fenouillet, E.
Right arrow Articles by Jones, I. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents

CORRESPONDENCE

To the editor:

HIV Env reduction postreceptor binding: a new target for AIDS treatment?

Markovic et al1 confirmed recently a role for an oxido-reductase activity, presumed to be that of protein disulfide isomerase (PDI), in the events that follow HIV envelope (Env) binding to cellular receptors. PDI action is thought to enable structural rearrangement of Env that precedes virus-cell fusion. A role for PDI was first reported in the seminal study by Ryser et al2 in 1994, who observed that the presence of PDI inhibitors during HIV interaction with lymphoid cells impaired infection. We confirmed their study in 2001 and, additionally, addressed the step at which blockade occurs by showing that PDI co-clustered with CD4-enriched regions of the lymphocyte surface is required for HIV/cell fusion.3 At this stage, the precise mechanism of PDI involvement—reorganization of the Env disulfide network to enable the conformation changes required for fusion or alteration of thiol/disulfide content of other cell surface antigens involved in fusion—was unclear. Recently, in concomitantly accepted manuscripts, we4 and Ryser et al5 provided biochemical evidence that reduction of gp120 disulfide bonds by PDI during interaction with the lymphocyte surface was required for fusion. We concluded that 2 disulfide bonds were cleaved in the process.4 Markovic et al1 reported that reduction occurs within a multimeric CD4/CXCR4/Env/PDI complex induced by Env binding to the cell surface, which enables gp41 to reach the fusogenic 6-helix bundle conformation.

The data are significant, as they indicate a new area for anti-HIV intervention through development of thiol-interchange inhibitors such as the experimental anti–tumor sulfonylurea analogs6 and bacitracin. Important steps in the process, however, remain unclear: the identification of which disulfides are cleaved and the precise stage in viral entry where cleavage occurs. The latter point is one of debate, as Env reduction has been observed following either CD41,5 or CXCR4 interaction.4 The capacity of the soluble forms of recombinant CD4 to promote Env binding to CXCR4 is more consistent with the PDI-independence of the Env-CXCR4 interaction.

That Env needs conversion by PDI in order to reach its fusogenic conformation highlights the role of cell surface catalysts in the generation of the fusion synapse and shows that the presence of the requisite receptors is not sufficient. In addition to Env, oxido-reduction of CD4 has been observed during HIV/cell fusion.7 Originally suggested as a requirement for fusion, we suggest, in the light of the data reported above, that CD4 redox change is a consequence of Env reduction and not an independent mechanism. Plausibly, the D2 domain, which does not play an active function in Env binding, acts in a donor/acceptor capacity to enable the gp120 reduction.

In addition to drug development, and as noted in a commentary here by Kornbluth,8 partially reduced Env may constitute a vaccine candidate capable of eliciting neutralizing antibodies directed against epitopes masked on the native antigen. Encouragingly, if the required antibodies could be induced, the half-life of the fusion intermediate at the cell surface appears sufficient4 to enable antibody binding to occur.

Emmanuel Fenouillet, Rym Barbouche, and Ian M. Jones

Correspondence: Emmanuel Fenouillet, Department of Biochemistry, CNRS School of Medicine, Blvd Dramard, Marseille, 13015 France; e-mail: fenouillet.e{at}jean-roche.univ-mrs.fr

References

  1. Markovic I, Stantchev TS, Fields KH, et al. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood. 2004;103: 1586-1594.[Abstract/Free Full Text]

  2. Ryser HJ, Levy EM, Mandel R, DiSciullo GJ. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci U S A. 1994;91: 4559-4563.[Abstract/Free Full Text]

  3. Fenouillet E, Barbouche R, Courageot J, Miquelis R. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 binding. J Infect Dis. 2001;183: 744-752.[CrossRef][Medline] [Order article via Infotrieve]

  4. Barbouche R, Miquelis R, Jones IM, Fenouillet E. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J Biol Chem. 2003;278: 3131-3136.[Abstract/Free Full Text]

  5. Gallina A, Hanley TM, Mandel R, et al. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem. 2002;277: 50579-50588.[Abstract/Free Full Text]

  6. Morre DJ, Jacobs E, Sweeting M, de Cabo R, Morre DM. A protein disulfidethiol interchange activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4 methylphenyl sulfonyl)-N'-(4-chlorophenyl) urea (LY181984). Biochim Biophys Acta. 1997;1325: 117-125.[Medline] [Order article via Infotrieve]

  7. Matthias LJ, Yam PT, Jiang XM, et al. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol. 2002;3: 727-732.[Medline] [Order article via Infotrieve]

  8. Kornbluth RS. HIV envelope becomes unhinged by PDI for entry. Blood. 2004; 103: 1567.[Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry
Ingrid Markovic, Tzanko S. Stantchev, Karen H. Fields, Linda J. Tiffany, Melanija Tomiç, Carol D. Weiss, Christopher C. Broder, Klaus Strebel, and Kathleen A. Clouse
Blood 2004 103: 1586-1594. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
R. Barbouche, H. Lortat-Jacob, I. M. Jones, and E. Fenouillet
Glycosaminoglycans and Protein Disulfide Isomerase-Mediated Reduction of HIV Env
Mol. Pharmacol., April 1, 2005; 67(4): 1111 - 1118.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fenouillet, E.
Right arrow Articles by Jones, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fenouillet, E.
Right arrow Articles by Jones, I. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020